Murine Bone Marrow Stromal Progenitor Cells Elicit an In Vivo Cellular and Humoral Alloimmune Response Andrea T. Badillo, Kirstin J. Beggs, Elisabeth.

Slides:

Advertisements

Similar presentations

Heather J. Symons, Moshe Y

Advertisements

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

High-Risk Acute Lymphoblastic Leukemia Cells with bcr-abl and Ink4a/Arf Mutations Retain Susceptibility to Alloreactive T Cells Faith M. Young, Andrew.

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell.

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation.

Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A

Chronic graft-versus-host disease after granulocyte colony-stimulating factor-mobilized allogeneic stem cell transplantation: the role of donor T-cell.

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Weiqing Jing,

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad,

Following the Development of a CD4 T Cell Response In Vivo

Induction of heme oxygenase-1 before conditioning results in improved survival and reduced graft-versus-host disease after experimental allogeneic bone.

Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.

Macrophages from C3-deficient mice have impaired potency to stimulate alloreactive T cells by Wuding Zhou, Hetal Patel, Ke Li, Qi Peng, Marie-Bernadette.

Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.

IL-12hi Rapamycin-Conditioned Dendritic Cells Mediate IFN-γ–Dependent Apoptosis of Alloreactive CD4+ T Cells In Vitro and Reduce Lethal Graft-Versus-Host.

Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.

by Éric Aubin, Réal Lemieux, and Renée Bazin

Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer.

Immune Tolerance to Self-Major Histocompatability Complex Class II Antigens after Bone Marrow Transplantation: Role of Regulatory T Cells Allan D. Hess,

PreImplantation Factor Reduces Graft-versus-Host Disease by Regulating Immune Response and Lowering Oxidative Stress (Murine Model) Yehudith Azar, Reut.

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

Growth and Differentiation Advantages of CD4+OX40+ T Cells from Allogeneic Hematopoietic Stem Cell Transplantation Recipients Takero Shindo, Takayuki.

Treatment with a Rho Kinase Inhibitor Improves Survival from Graft-Versus-Host Disease in Mice after MHC-Haploidentical Hematopoietic Cell Transplantation

Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Cotransplantation of Ex Vivo Expanded and Unexpanded Cord Blood Units in Immunodeficient Mice Using Insulin Growth Factor Binding Protein-2–Augmented.

Inhibition of Cathepsin S Reduces Allogeneic T Cell Priming but Not Graft-versus-Host Disease Against Minor Histocompatibility Antigens Hisaki Fujii,

Sequential Expression of Adhesion and Costimulatory Molecules in Graft-versus-Host Disease Target Organs after Murine Bone Marrow Transplantation across.

Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses

Xinchun Chen, Yi Zeng, Gang Li, Nicolas Larmonier, Michael W

Blocking Activator Protein 1 Activity in Donor Cells Reduces Severity of Acute Graft- Versus-Host Disease through Reciprocal Regulation of IL-17–Producing.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

Volume 13, Issue 1, Pages (January 2006)

Bone Marrow–Derived Mesenchymal Stromal Cells from Patients with Sickle Cell Disease Display Intact Functionality Elizabeth O. Stenger, Raghavan Chinnadurai,

Lisa A. Palmer, George E. Sale, John I

T Cell–Mediated Rejection of Human CD34+ Cells Is Prevented by Costimulatory Blockade in a Xenograft Model Annie L. Oh, Dolores Mahmud, Benedetta Nicolini,

Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells

T Cell and B Cell Immunity can be Reconstituted with Mismatched Hematopoietic Stem Cell Transplantation Without Alkylator Therapy in Artemis-Deficient.

Effect of Ex Vivo Culture of CD34+ Bone Marrow Cells on Immune Reconstitution of XSCID Dogs Following Allogeneic Bone Marrow Transplantation Douglas.

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Atul Sathe, Sterling B. Ortega, Dorothy I. Mundy, Robert H

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

Elevation of Intracellular Cyclic AMP in Alloreactive CD4+ T Cells Induces Alloantigen- Specific Tolerance That Can Prevent GVHD Lethality In Vivo Matthew.

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

STAT1 acts as a tumor promoter for leukemia development

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

B7.2−/− Mature Dendritic Cells Generate T-Helper 2 and Regulatory T Donor Cells in Fetal Mice after In Utero Allogeneic Bone Marrow Transplantation Swati.

Role of B cells in TH cell responses in a mouse model of asthma

Volume 13, Issue 2, Pages (February 2006)

Contact Hypersensitivity in MHC Class II-Deficient Mice Depends on CD8 T Lymphocytes Primed by Immunostimulating Langerhans Cells Anne Bouloc, Andrea.

CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic.

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells Christian Scheffold, Yolanda C. Scheffold,

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Volume 31, Issue 4, Pages (October 2009)

Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G

Susan M. Kaech, Scott Hemby, Ellen Kersh, Rafi Ahmed Cell

Volume 71, Issue 11, Pages (June 2007)

Volume 62, Issue 1, Pages (July 2002)

Moutih Rafei, Elena Birman, Kathy Forner, Jacques Galipeau

Mattias Svensson, Asher Maroof, Manabu Ato, Paul M. Kaye Immunity

Volume 31, Issue 5, Pages (November 2009)

Presentation transcript:

Murine Bone Marrow Stromal Progenitor Cells Elicit an In Vivo Cellular and Humoral Alloimmune Response Andrea T. Badillo, Kirstin J. Beggs, Elisabeth H. Javazon, Jessica C. Tebbets, Alan W. Flake Biology of Blood and Marrow Transplantation Volume 13, Issue 4, Pages 412-422 (April 2007) DOI: 10.1016/j.bbmt.2006.12.447 Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Immune phenotype of AmSPC ± IFN-γ. AmSPC express MHC I constitutively but do not express MHC II or the costimulatory molecules CD40, CD80, and CD86. With IFN-γ pretreatment (200 ng/mL for 72 h), MHC I expression is upregulated and MHC II expression is induced, but costimulatory marker expression remains unchanged. Biology of Blood and Marrow Transplantation 2007 13, 412-422DOI: (10.1016/j.bbmt.2006.12.447) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 AmSPC inhibition of T cell proliferation. Representative histogram demonstrating direct coculture of AmSPC with mixed lymphocyte cultures. The presence of B6 responder-matched or Balb/c stimulator-matched AmSPC results in inhibition of B6 responder CD4+ and CD8+ proliferation in both mitogen and alloantigen (Balb/c splenocyte) stimulated cultures (A). Transwell separation of AmSPC (lower chamber) from splenocytes (upper chamber) does not result in T cell inhibition (B). Response is measured by CFDA-SE divisions—each division halves the fluorescence intensity moving the population to the left on the histogram. (1 = CD4+ fraction of PHA stimulated cells, 2 = CD8+ fraction of PHA stimulated culture, 3 = CD4+ fraction of alloantigen stimulated culture, 4 = CD8+ fraction of alloantigen stimulated culture.) Biology of Blood and Marrow Transplantation 2007 13, 412-422DOI: (10.1016/j.bbmt.2006.12.447) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Six-week posttreatment T cell response after 7-day incubation with alloantigen. CD4+ T cells were isolated from spleens of B6 animals injected with either Balb/c (allogeneic) AmSPC, B6 (syngeneic) AmSPC, or uninjected animals. B6 CD4+ responder cells were stained with CFSE, and T cell proliferation in response to stimulation with alloantigen (Balb/c splenocytes) is indicated by decreases in the fluorescence intensity and histogram peak shifts to the left. (A) After 3.5 days of alloantigen stimulation, alloantigen-primed cells (green line) initiate T cell proliferation, whereas syngeneic primed (blue line) and uninjected cells (pink line) have not begun to divide. (B) After 5.5 days in coculture, more than half of allogeneic-primed cells (green line) have proliferated and are represented as a single left peak comprised of a heterogenous number of cell divisions. In comparison, syngeneic-primed cells (blue line) have just begun to proliferate. At the end of 7 days in coculture, all responder populations demonstrate a proliferative response compared to unstimulated controls (purple filled curve). Biology of Blood and Marrow Transplantation 2007 13, 412-422DOI: (10.1016/j.bbmt.2006.12.447) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Alloantibody response of animals transplanted with AmSPC. Untreated target Balb/c AmSPC and IFN-γ-treated Balb/c target AmSPC were incubated with varying dilutions of mouse serum from 0, 2, 4, 5, and 6 weeks postpriming with Balb/c (allogeneic) AmSPC (a) and B6 (syngeneic) AmSPC (b). IgG and IgM antibody binding was measured by flow cytometric analysis. High alloantibody titers were found in animals injected with Balb/c (allogeneic) AmSPC compared to low titers exhibited in animals treated with B6 (syngeneic) AmSPC. Biology of Blood and Marrow Transplantation 2007 13, 412-422DOI: (10.1016/j.bbmt.2006.12.447) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Antibody binding to third-party AmSPC targets. (A) IgG titers detected from serum of animals primed with Balb/c (allogeneic) AmSPC at 6 weeks posttreatment and incubated with Balb/c AmSPC targets. (B) IgG titers detected using serum from the same animals incubated with CBA (third-party) AmSPC targets. Green line = 1:10 dilution, pink line = 1:100 dilution, blue line = 1:1000 dilution. Biology of Blood and Marrow Transplantation 2007 13, 412-422DOI: (10.1016/j.bbmt.2006.12.447) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Kaplan-Meier analysis of skin graft survival. B6 mice treated with Balb/c (allogeneic) AmSPC or allogeneic splenocytes exhibited earlier rejection of Balb/c skin grafts compared to animals treated with B6 (syngeneic) AmSPC, syngeneic splenocytes, or untreated controls (P < .05). Biology of Blood and Marrow Transplantation 2007 13, 412-422DOI: (10.1016/j.bbmt.2006.12.447) Copyright © 2007 American Society for Blood and Marrow Transplantation Terms and Conditions